Log in | Register

Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics, and prognostic significance

Francis Schneider| Charlotte Bach| Hélène Chung| Luca Crippa| Thomas Lavaux| Pierre-Edouard Bollaert| Michel Wolff| Angelo Corti| Anne Launoy| Xavier Delabranche| Thierry Lavigne| Nicolas Meyer| Patrick Garnero| Marie-Hélène Metz-Boutigue
Original
Volume 38, Issue 9 / September , 2012

Pages 1514 - 1522

Abstract

Purpose

Chromogranin A (CGA) is released in the plasma during life-threatening illnesses. Its N-terminal 1–76 peptide, vasostatin-I (VS-I), has never been assessed in critically ill patients. Our aim was to examine whether the admission VS-I concentration has prognostic significance without having to specify a primary diagnosis.

Methods

VS-I concentrations were assessed with a new ELISA in 481 consecutive patients and 13 healthy controls. CGA and standard biological tests (including lactate) were performed; the simplified acute physiological score II (SAPS II) was calculated. Mortality was assessed at day 28. In a subgroup of 13 patients with shock, serial VS-I doses were given over 60 h.

Results

Critically ill patients had higher admission VS-I concentrations than controls [4.06 (2.78; 7.61) vs. 2.85 (2.47; 3.22) ng/ml, p < 0.001]. The plasma VS-I concentration was significantly lower in survivors than in non-survivors [3.70 (2.67; 6.12) vs. 5.75 (3.65; 11.20) ng/ml] and in the absence of shock [3.58 (2.59; 5.05) vs. 5.93 (3.30; 11.06) ng/ml, p < 0.001]. The survival rate was better in patients with VS-I concentrations under the median value of 3.97 ng/ml (p < 0.001). Admission VS-I and lactate values were independent predictors of mortality (p < 0.01). Moreover, taking them together, combined with age, provided a better indication for predicting mortality than taking each alone (p < 0.01).

Conclusions

Significant amounts of VS-I are detected on admission in critically ill patients. A plasma VS-I concentration above 3.97 ng/ml is associated with poor outcome, and in routine practice simultaneous measurements of the three independent factors VS-I, lactate and age can affect the assessment of severity.

Keywords

References

  1. Banks P, Helle KB (1965) The release of proteins from the stimulated adrenal medulla. Biochem J 97:40C–41C
    • View reference on PubMed
  2. Helle KB, Corti A, Metz-Boutigue MH, Tota B (2007) The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 64:2863–2886
    • View reference on PubMed
    • View reference on publisher's website
  3. Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D (1993) Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur J Biochem 217:247–257
    • View reference on PubMed
    • View reference on publisher's website
  4. Aardal S, Helle KB (1992) The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 41:9–18
    • View reference on PubMed
    • View reference on publisher's website
  5. Aardal S, Helle K, Elsayed S, Reed R, Serck-Hanssen G (1993) Vasostatins, comprising the N-terminal domain of chromogranin A, supress tension in isolated human blood vessel segments. J Neuroendocrinol 5:405–412
    • View reference on PubMed
    • View reference on publisher's website
  6. Tota B, Quintieri AM, Di Felice V, Cerra MC (2007) New biological aspects of chromogranin A-derived peptides: focus on vasostatins. Comp Biochem Physiol A Physiol 147:11–18
    • View reference on publisher's website
  7. Tota B, Cerra MC, Gattuso A (2010) Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a “whip-brake” system of the endocrine heart. J Exp Biol 213:3081–3103
    • View reference on PubMed
    • View reference on publisher's website
  8. Lugardon K, Raffner R, Goumon Y, Corti A, Delmas A, Bulet P, Aunis D, Metz-Boutigue MH (2000) Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 275:10745–10753
    • View reference on PubMed
    • View reference on publisher's website
  9. Bone RC (2008) Towards an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 268:3452–3455
    • View reference on publisher's website
  10. Wortsman J, Frank S, Cryer PE (1984) Adrenomedullary response to maximal stress in humans. Am J Med 77:779–784
    • View reference on PubMed
    • View reference on publisher's website
  11. Zhang D, Lavaux T, Voegeli AC, Lavigne T, Castelain V, Meyer N, Sapin R, Aunis D, Metz-Boutigue MH, Schneider F (2008) Prognostic Value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin Chem 54:1497–1503
    • View reference on PubMed
    • View reference on publisher's website
  12. Pachot A, Lepape A, Vey S, Bienvenu J, Mougin B, Monneret G (2006) Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol Lett 106:63–71
    • View reference on PubMed
    • View reference on publisher's website
  13. Dulhunty JM, Lipman J, Finfer S Sepsis Study Investigators for the ANZICS Clinical Trials Group (2008) Does severe non-infectious SIRS differ from severe sepsis? Results from a multi-centre Australian and New Zealand intensive care unit study. Intensive Care Med 34:1654–1661
  14. Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963
    • View reference on PubMed
    • View reference on publisher's website
  15. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Belloci F, Crea F, Maseri A (2007) Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 28:1117–1127
    • View reference on PubMed
    • View reference on publisher's website
  16. Degorce F, Goumon Y, Jacquemart L, Vidaud C, Bellanger L, Pons-Anicet D, Seguin P, Metz-Boutigue MH, Aunis D (1999) A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145–245). Brit J Cancer 79:65–71
    • View reference on PubMed
    • View reference on publisher's website
  17. Hanley J, McNeil B (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843
    • View reference on PubMed
  18. Corti A, Sanchez LP, Gasparri A, Curnis F, Longhi R, Brandazza A, Siccardi AG, Sidoli A (1997) Production and structure characterisation of recombinant chromogranin A N-terminal fragments (vasostatins)—evidence of dimer-monomer equilibria. Eur J Biochem 248:692–699
    • View reference on PubMed
    • View reference on publisher's website
  19. Stridsberg M, Angeletti RH, Helle KB (2000) Characterisation of N-terminal chromogranin A and chromogranin B in mammals by region-specific radioimmunoassays and chromatographic separation methods. J Endocrinol 165:703–714
    • View reference on PubMed
    • View reference on publisher's website
  20. Yoo SH, Lewis MS (1993) Dimerization and tetramerization properties of the C-terminal region of chromogranin A: a thermodynamic analysis. Biochemistry 32:8816–8822
    • View reference on PubMed
    • View reference on publisher's website
  21. Hsiao RJ, Mezger MS, O’Connor D (1990) Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 37:955–964
    • View reference on PubMed
    • View reference on publisher's website
  22. Rosjo H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland T, GISSI-HF Investigators (2010) Prognostic value of chromogranin A in chronic heart failure: data from th GISSI-heart failure trial. Eur J Heart Fail 12:549–556
    • View reference on PubMed
    • View reference on publisher's website
  23. Hörl WH, Wanner C, Schollmeyer P (1987) Proteinases in catabolism and malnutrition. JPEN 11(5 suppl):98S–103S
    • View reference on publisher's website
  24. Pham CTN (2006) Neutrophil serine proteases: specific regulators of inflammation. Nat Rev 6:541–550
    • View reference on publisher's website
  25. Yazdan-Ashoori P, Liaw P, Toltl L, Webb B, Kilmer G, Carter DE, Fraser DD (2011) Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis. J Crit Care 26:556–565
    • View reference on PubMed
    • View reference on publisher's website
  26. Lauhio A, Hästbacka J, Pettilä V, Tervahartiala T, Karlsson S, Varpula T, Varpula M, Ruokonen E, Sorsa T, Kolo E (2011) Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res 64:590–594
    • View reference on PubMed
    • View reference on publisher's website
  27. Lee WL, Downey GP (2000) Coagulation inhibitors in sepsis and disseminated intravascular coagulation. Intensive Care Med 26:1701–1706
  28. Parmer RJ, Mahata SK, Jiang O, Taupenot L, Gong Y, Mahata M, O’Connors DT, Miles LA (2000) Tissue plasminogen activator and chromaffin cell function. Adv Exp Med Biol 428:179–191
  29. Hsiao RJ, Neumann HP, Parmer RJ, Barbosa JA, O’Connor DT (1990) Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am J Med 88:607–613
    • View reference on PubMed
    • View reference on publisher's website
  30. Groeneveld AB, van Lambalgen TA, Thijs LG (1986) Microvascular permeability in endotoxin and bacterial shock. Acute Care 12:195–218
    • View reference on PubMed
  31. Seidah NG, Chrétien M (1999) Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 848:45–62
    • View reference on PubMed
    • View reference on publisher's website
  32. Roatta S, Passatore M, Novello M, Colombo B, Dondossola E, Mohammed M, Losano G, Corti A, Helle KB (2011) The chromogranin A-derived N-terminal peptide vasostatin-I: in vivo effects on cardiovascular variables in the rabbit. Regul Pept 168:10–20
    • View reference on PubMed
    • View reference on publisher's website
  33. Trzeciak S, Dellinger RP, Chansky ME, Arnold RC, Schorr C, Milcarek B, Hollenberg SM, Parillo JE (2007) Serum lactate as a predictor of mortality in patients with infection. Intensive Care Med 33:970–977
  34. Taupenot L, Harper KL, O’Connor DT (2003) The chromogranin-secretogranin family. N Eng J Med 348:1134–1149
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement